National Cancer Institute; Notice of Meeting, 8691 [2024-02592]

Download as PDF Federal Register / Vol. 89, No. 27 / Thursday, February 8, 2024 / Notices Dated: February 2, 2024. Lauren Fleck, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health [FR Doc. 2024–02526 Filed 2–7–24; 8:45 am] National Institute on Drug Abuse; Notice of Closed Meetings BILLING CODE 4140–01–P lotter on DSK11XQN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; FieldDeployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment. Date: March 6, 2024. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892. Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443–4577, caitlin.moyer@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA L Conflict SEP. Date: March 15, 2024. Time: 2:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892. Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443–4577, sudhirkumar.yanpallewar@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) VerDate Sep<11>2014 17:34 Feb 07, 2024 Jkt 262001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Council of Research Advocates. The meeting will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend in-person or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: https:// videocast.nih.gov. Name of Committee: National Cancer Institute Council of Research Advocates. Date: March 5, 2024. Time: 10:00 a.m. to 3:00 p.m. Agenda: Welcome and Chairwoman’s Remarks, NCI Director’s Update, NCI Updates, and Legislative Update. Place: Porter Neuroscience Research Center, National Institutes of Health, Building 35A, Room 610, 35 Convent Drive, Bethesda, MD 20892–2580 (Hybrid Meeting). Contact Person: Amy Williams, Acting Director, NCI Office of Advocacy Relations, National Cancer Institute, NIH, 31 Center Drive, Building 31, Room 10A28, Bethesda, MD 20892, (240) 781–3406, williaam@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: NCRA: https:// PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 8691 deainfo.nci.nih.gov/advisory/ncra/ncra.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: February 5, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–02592 Filed 2–7–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Eunice Kennedy Shriver National Institute of Child Health and Human Development Special Emphasis Panel; HEAL Initiative: Limited Competition: Clinical Outcomes of Babies with Opioid Exposure (OBOE) Study (UG1). Date: March 25, 2024. Time: 9:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Kimberly L. Houston, M.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health & Human Development, NIH, 6710B Rockledge Drive, Rm. 2137C, Bethesda, MD 20892, (301) 827–4902, kimberly.houston@ nih.gov. E:\FR\FM\08FEN1.SGM 08FEN1

Agencies

[Federal Register Volume 89, Number 27 (Thursday, February 8, 2024)]
[Notices]
[Page 8691]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02592]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Cancer 
Institute Council of Research Advocates.
    The meeting will be a hybrid meeting held in-person and virtually 
and will be open to the public as indicated below, with attendance 
limited to space available. Individuals who plan to attend in-person or 
view the virtual meeting and need special assistance or other 
reasonable accommodations, should notify the Contact Person listed 
below in advance of the meeting. The meeting can be accessed from the 
NIH Videocast at the following link: https://videocast.nih.gov.

    Name of Committee: National Cancer Institute Council of Research 
Advocates.
    Date: March 5, 2024.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: Welcome and Chairwoman's Remarks, NCI Director's Update, 
NCI Updates, and Legislative Update.
    Place: Porter Neuroscience Research Center, National Institutes 
of Health, Building 35A, Room 610, 35 Convent Drive, Bethesda, MD 
20892-2580 (Hybrid Meeting).
    Contact Person: Amy Williams, Acting Director, NCI Office of 
Advocacy Relations, National Cancer Institute, NIH, 31 Center Drive, 
Building 31, Room 10A28, Bethesda, MD 20892, (240) 781-3406, 
[email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has procedures at https://www.nih.gov/about-nih/visitor-information/campus-access-security for 
entrance into on-campus and off-campus facilities. All visitor 
vehicles, including taxicabs, hotel, and airport shuttles will be 
inspected before being allowed on campus. Visitors attending a 
meeting on campus or at an off-campus federal facility will be asked 
to show one form of identification (for example, a government-issued 
photo ID, driver's license, or passport) and to state the purpose of 
their visit.
    Information is also available on the Institute's/Center's home 
page: NCRA: https://deainfo.nci.nih.gov/advisory/ncra/ncra.htm, where 
an agenda and any additional information for the meeting will be 
posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: February 5, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02592 Filed 2-7-24; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.